Pharmasset - Tapping Both IFN and IFN-Free Opportunities
Bristol-Myers announced topline PhII data of its once daily NS5A inhibitor (BMS-790052) +Peg-IFN/RBV. Efficacy data of BMS-790052 raises the probability of success of the ongoing trial of PSI-7977 + BMS-790052 (PhIIb, Nucleotide + NS5A inhibitor) - Once daily w/o IFN. PSI-7977+ Peg-IFN/RBV have shown advantage over the approved drugs and other drugs in the pipeline, besides promising of IFN-free combinations. For more details, please read our report released on 21th September, 2011 on VRUS titled “Tapping Both IFN and IFN-Free Opportunities”.
COMPANIES MENTIONED
Pharmasset
Pharmasset
